A new study found that continuous glucose monitors can cut healthcare costs by about 20% while also improving outcomes for insulin-dependent diabetes patients, largely by reducing hospitalizations and emergency department visits. Despite these benefits and broad insurance coverage, roughly 80% of eligible patients still are not using the technology — highlighting a significant adoption gap.
Over-the-counter continuous glucose monitors have been available for people with and without diabetes for more than a year now — but the data they collect doesn’t seem to be as useful for nondiabetic users, according to new research from Mass General Brigham.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.
Abbott and Medtronic — typically regarded as competitors — have recently joined forces. The two companies teamed up to collaborate on a continuous glucose monitoring system that combines Abbott’s FreeStyle Libre technology with Medtronic’s automated insulin delivery system.
Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Now more than ever, enhancing primary care practices to include CGM capabilities is a crucial goal requiring the support and involvement of the broader healthcare community.
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.
In an interview at the J.P. Morgan Healthcare Conference in San Francisco earlier this week, the CEO of Dexcom relayed a strong desire to sell CGM systems directly to the consumers with possible pilots this year.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom's continuous glucose monitoring system can sync their data on the Livongo platform.
On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.
Medtronic had previously betted on higher adoption of its insulin pumps tethering the use of continuous glucose monitors to those pumps but has recently returned to the standalone CGM market with the launch of its Guardian Connect device in the U.S. Should Dexcom and Abbott worry?